Publications

Search our bibliography using the filters on the right-hand side.

Displaying 251 through 300 of 2394 publications.

Abdulkareem NM, Bhat R, Powell RT, Chikermane S, Yande S, Trinh L, Abdelnasser HY, Tabassum M, Ruiz A, Sobieski M, Nguyen ND, Johnson M, Kaipparettu BA, Johnson CA, Bond RA, Stephan C, Triveni MV. Screening of GPCR drugs for repurposing in breast cancer. Front Pharmacol. 2022 Dec 6;13:1049640. doi: 10.3389/fphar.2022.1049640

Goyal RK, Zhang J, Davis KL, Kaufman PA. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior PI3K inhibitor therapy for metastatic breast cancer. Poster presented at the 2022 San Antonio Breast Cancer Symposium (SABCS); December 6, 2022. San Antonio, TX.

Zhang Y, Mayorga ME, Ivy J, Hassmiller Lich K, Swann JL. Modeling the impact of nonpharmaceutical interventions on COVID-19 transmission in K-12 schools. MDM Policy Pract. 2022 Dec 3;7(2):238146832. doi: 10.1177/23814683221140866

Shih JY, Lin SH, Nagar SP, Davis KL, Jimenez MI, Kahangire DA, Servidio L, Ho L, Veluswamy R. Treatment patterns in resectable early-stage NSCLC in Taiwan: subgroup analysis of a global real-world study. Poster presented at the 2022 ESMO Asia Congress; December 2, 2022. Singapore, Republic of Singapor.

Razavi M, Herring W, Gillis C, Maserejian N, Pemberton-Ross P, Nejati M. Economic burden of daily transitions to later stages of AD dementia in the US. Poster presented at the 15th Clinical Trials on Alzheimer's Disease (CTAD); December 2, 2022. San Francisco, CA.

Ni L, Diamantogiannis F, Teitsson S, Knight C. Cost-effectiveness analysis of nivolumab as an adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in Greece. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S120. doi: 10.1016/j.jval.2022.09.580

Paret K, Ronquest N, Droege M. Economic modeling considerations for rare neurodegenerative diseases of infancy and early childhood. Poster presented at the ISPOR Europe 2022; November 9, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S171. doi: 10.1016/j.jval.2022.09.830

Paret K, Beyhaghi H, Herring W, Rousculp M, Toback S, Mauskopf J. Assessing the cost-effectiveness of the Novavax COVID-19 vaccine as a potential booster vaccine option for adults in the United States. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S89. doi: 10.1016/j.jval.2022.09.434

Mellott C, Jaworski R, Carrico J, Clinkscales M, Talbird S, Dobrowolska I, Golicki D, Tsoumani E, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S117. doi: 10.1016/j.jval.2022.09.568

Lopez A, del Amo M, Perdizet J, McDade C, Wilson M. Comparing the public health impact of a 15- or 20-valent pneumococcal conjugate vaccine pediatric national immunization program in Spain. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S99. doi: 10.1016/j.jval.2022.09.482

Talbird S, Graham J, Anderson S, Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Health and economic impact of a novel 3-antigen vaccine for the prevention of hepatitis B in adults in Germany: a cost-effectiveness analysis. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S135. doi: 10.1016/j.jval.2022.09.649

Talbird S, Graham J, Anderson S, Nossov M, Beattie N, Lains Sousa C, Rak A, Masters III H, Diaz-Mitoma F. Cost-effectiveness and epidemiological impact of a novel 3-antigen vaccine for the prevention of Hepatitis B in adults in the United Kingdom. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. doi: 10.1016/j.jval.2022.09.782

Carrico J, Hicks K, Panozzo CA, Ghaswalla P. Economic burden of respiratory syncytial virus in adults in the United States. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec; 25(12):S65. doi: 10.1016/j.jval.2022.09.315

Salem A, Curran D, Carrico J, La EM, Lorenc S, Hicks K, Poston S, Carpenter CF. Public health impact and cost-effectiveness of recombinant zoster vaccine for vaccinating immunocompromised adults against herpes zoster in the United States. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S159. doi: 10.1016/j.jval.2022.09.767

Li X, Hodgson D, Flaig J, Kieffer A, Herring W, Beyhaghi H, Willem L, Jit M, Bilcke J, Beutels P. Cost-effectiveness of Respiratory Syncytial Virus (RSV) prevention interventions in children: a model comparison study. Poster presented at the ISPOR Europe 2022; November 9, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec; 25(12S):S178. doi: 10.1016/j.jval.2022.09.861

Herring W, Shen Q, Zhang Y, Martin A, Otiker T, Zhang W. The relationship between Asthma Control Questionnaire scores and exacerbation risk, resource utilization, and utility values: an analysis from the CAPTAIN trial. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S36. doi: 10.1016/j.jval.2022.09.174

Kamgar F, Ho S, Hawe E, Brodtkorb TH. A review of treatment effect waning methods for immuno-oncology therapies in National Institute for Health and Care Excellence technology appraisals. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S98. doi: 10.1016/j.jval.2022.09.476

Kamgar F, Thybo SH, Johannesen K, Teitsson S, Brodtkorb TH. Cost-effectiveness of nivolumab as an adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence with tumor cell pd-l1 expression ≥ 1% in Denmark. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S146. doi: 10.1016/j.jval.2022.09.706

Kamgar F, Johannesen K, Thybo SH, Teittson S, Brodtkorb TH. Cost-effectiveness of nivolumab for the adjuvant treatment of muscle-invasive urothelial carcinoma patients with high risk of recurrence and tumor cell pd-l1 expression ≥ 1% in Sweden. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S146. doi: 10.1016/j.jval.2022.09.707

Oniangue-Ndza C, Strittmatter G, Lucas A, Wilson M, Kassahun S, Singh P. Pharmacoeconomic analysis of adjuvant nivolumab for patients with resected esophageal or gastroesophageal junction cancer in Switzerland. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S95. doi: 10.1016/j.jval.2022.09.464

Zinan Y, Graham J, Diaz-Decaro J, Myers E, Lumley M, Buck P. The public health impact of routine vaccination in 16- to 40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United Kingdom. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S200-1. doi: 10.1016/j.jval.2022.09.972

Hancock H, Brockbank J, Theodorou E, Brodtkorb TH. Survival analysis methods used in immuno-oncology NICE appraisals. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S92. doi: 10.1016/j.jval.2022.09.451

Hancock H, Brockbank J, Brodtkorb TH, Lucherini S, Russell J. A review of cure assumptions implemented in early-stage oncology NICE appraisals. Poster presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S148. doi: 10.1016/j.jval.2022.09.714

Yucel E, Hartley L, Bell J, Wolowacz S, Kamgar F, Hawe E. A systematic literature review of utility estimates for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S395. doi: 10.1016/j.jval.2022.09.1964

Yucel E, Lunan M, Hartley L, Ahdesmaki O, Bull R, Hawe E. A systematic literature review of prognostic factors and surrogate endpoint analyses in chronic lymphocytic leukemia and small lymphocytic lymphoma. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S35. doi: 10.1016/j.jval.2022.09.169

Bahloul D, Tavi J, Thomas RB, Conlon S, Harold S, Moss E. Economic burden and quality of life in prurigo nodularis: a systematic literature review. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S176-7. doi: /10.1016/j.jval.2022.09.854

Bullard JT, Kowalkowski M, Sparling A, Roberge J, Barkley JE. A retrospective evaluation of the impacts of a multidisciplinary care model for managing patients with advanced illness on acute care utilization and quality of care at end of life. J Palliat Med. 2022 Dec;25(12):1835-43. doi: 10.1089/jpm.2022.0264

Vickers A. A comparison of the performance of a range of trial-level surrogacy methods. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S357. doi: 10.1016/j.jval.2022.09.1771

Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194

Ronquest N, Clinkscales M, Paret K. How are United States ICER'S evidence ratings determined?: A systematic review of ICER'S evidence ratings in evidence reports for new drugs in 2020 and 2021. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):299-300. doi: 10.1016/j.jval.2022.09.1479

Basarir H, Mauskopf J, McCrink L, Karmarkar T, O'Brien M. A systematic literature review of rationale, methods, and use of cost-effectiveness thresholds in health technology assessments. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S330-1. doi: 10.1016/j.jval.2022.09.1634

Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jimenez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martinez-Lopez J, Wang Y, Link BK. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022 Nov 22;6(22):5835-43. doi: 10.1182/bloodadvances.2022008150

Herring WL. Determining the value of disease-modifying therapies for Alzheimer's disease. Presented at the JIM Symposium at Karolinska Institutet; November 11, 2022. Stockholm, Sweden.

Xu X, Chehade M, Kwiatek J, Maslova E, Kielar D, Stirnadel-Farrant H, Meyers J, Aceves S. Demographics and clinical characteristics of patients with eosinophilic esophagitis: a US-based insurance claims data analysis. Poster presented at the 2022 ACAAI Annual Scientific Meeting; November 10, 2022. Louisville, KY.

Wolowacz S, Bhatnagar V, Vickers A, Pickaert AP. Clinical evidence for health technology assessment in oncology, are we going backwards? Where are we going with single-arm trials? Presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria.

Brodtkorb TH. Does the choice of cost-effectiveness model approach matter? Presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria.

Wolowacz S. Incorporating informal care considerations in HTA. Presented at the ISPOR Europe 2022; November 7, 2022.

Bonastre J, Negrier S, Colrat F, Chamielec C, Teitsson S, Knight C, Ni L, Chevalier J, Gaudin AF, Roupret M, Branchoux S. Impact of method for modelling distant recurrence (DR) on cost-effectiveness (CE) of nivolumab (NIVO) as an adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC) patients with high risk of recurrence in France. Presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria.

Moss E, Burrell AD, Lee JC, Reichenbach D, Mitchell SE, Yan S, Thiruvillakkat K. Structured literature review of the economic and humanistic burden in kidney allograft loss. Poster presented at the American Society of Nephrology (ASN) Kidney Week 2022 Annual Meeting; November 3, 2022. Orlando, FL. [abstract] J Am Soc Nephrol. 2022 Nov; 33(2002):826.

Poirrier JE, DeMartino JK, Nagar S, Carrico J, Hicks K, Meyers J, Stoddard J. Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination. Hum Vaccin Immunother. 2022 Nov;18(5):2040328. doi: 10.1080/21645515.2022.2040328

Poirrier JE, Meyers JL, Nagar SP, Patterson BJ, Glasser LI, Jabbour SA. Herpes zoster incidence and burden in adults with type 2 diabetes in the U.S.: a retrospective database analysis. Diabetes Care. 2022 Nov 1;45(11):2585-93. doi: 10.2337/dc21-2053

Falope O, Nyaku MK, O'Rourke C, Hermany LV, Plavchak B, Mauskopf J, Hartley L, Kruk ME. Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs. Expert Rev Vaccines. 2022 Nov 1;21(11):1621-36. doi: 10.1080/14760584.2022.2116007

Mody R, Meyers J, Yu M, Davis K, Levine JA. Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States. Curr Med Res Opin. 2022 Nov;38(11):1785-95. doi: 10.1080/03007995.2022.2085962.

Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the HSG 2022 Annual Meeting; November 2022. Tampa, FL. [abstract] J Huntingtons Dis. 2022 Oct 31; 11(s1):S31. Previously presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting. doi: 10.3233/JHD-229005

Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch DA. Erratum for Earnshaw et al., Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Oct 26;10(5):e0303122. doi: 10.1128/spectrum.03031-22

Paret K, Beyhaghi H, Herring W, Rousculp M, Toback S, Mauskopf J. Population-level model of the health and economic impact of NVX-CoV2373 as a COVID-19 booster vaccine option for adults in the United States. Poster presented at the Society for Medical Decision Making (SMDM) 44th Annual North American Meeting; October 25, 2022. Seattle, WA.

Xu X, Kwiatek J, Chehade M, Aceves S, Maslova E, Kielar D, Stirnadel-Farrant H, Meyers J, Candrilli S, Katial R. Characteristics of and healthcare cost drivers among U.S. patients with eosinophilic esophagitis with high versus non-high all-cause costs: an analysis of insurance claims data. Poster presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting; October 24, 2022. Charlotte, NC.

Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8

Zhang Y, Mayorga M, Ivy J, Lich KH, Swann JL. Modeling the impact of non-pharmaceutical interventions on COVID-19 transmission in K-12 schools. Presented at the INFORMS Annual Meeting 2022; October 17, 2022. Indianapolis, IN.

George S, Carrico J, Hicks K, Loukov D, Kaan I, Ng C, Regan J, Giannelos N. Updated cost-utility and public health impact of recombinant zoster vaccine (RZV) in Canadians aged 50 years and older. Poster presented at the 2022 Canadian Association for Population Therapeutics Conference; October 17, 2022. Toronto, Canada.